Amyl Therapeutics, a University of Liege spinout, develops a pan-amyloid immunotherapy platform aimed at multiple amyloid-driven neurodegenerative diseases rather than a single target. Its lead approach is designed to clear several amyloid species implicated in Alzheimer's and related conditions. The financing is intended to validate the platform and move the lead programme toward clinical development.